More Images
Europe's Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for two vaccines: Fluad (surface antigen, inactivated, adjuvanted) and Flucelvax (surface antigen, inactivated, prepared in cell cultures) for active immunization against influenza. Together, the vaccines can immunize children from 2 years and older, adults, and those with comorbidities—including cardiovascular disease, diabetes, and obesity—against influenza.

The CHMP also recommended a revised composition for Nuvaxovid, an already approved vaccine that targets the JN.1 variant of the SARS-CoV-2 virus. The news follows recommendations by the European Medicines Agency Emergency Task Force to update COVID-19 vaccines for the 2024/2025 vaccination campaign.

The committee further recommended updating the composition of Bimervax, a similarly approved vaccine that targets the Omicron XBB.1.16 SARS-CoV-2 subvariant. All four recommendations are now pending approval from the European Commission. Head over to Medscape to read the full story.